Castle Biosciences is a company developing and commercializing diagnostic and prognostic tests for dermatologic cancers. It offers products for diagnosing cutaneous melanoma (DecisionDx-Melanoma, DecisionDx DiffDx-Melanoma, and DecisionDx-CMSeq), solutions for the prognosis and diagnosis of uveal melanoma (DecisionDx-UM, DecisionDx-UMSeq, and DecisionDx-PRAME), and a predictor of metastasis DecisionDx-SCC.